Renaissance Technologies LLC Sells 326,147 Shares of Iqvia Holdings Inc (IQV)

Share on StockTwits

Renaissance Technologies LLC cut its holdings in Iqvia Holdings Inc (NYSE:IQV) by 98.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,500 shares of the medical research company’s stock after selling 326,147 shares during the period. Renaissance Technologies LLC’s holdings in Iqvia were worth $549,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in IQV. First Trust Advisors LP bought a new position in Iqvia in the second quarter worth approximately $99,127,000. BlackRock Inc. raised its position in shares of Iqvia by 5.7% during the 2nd quarter. BlackRock Inc. now owns 10,170,048 shares of the medical research company’s stock valued at $1,015,173,000 after purchasing an additional 546,878 shares during the period. Retirement Systems of Alabama raised its position in shares of Iqvia by 374.0% during the 2nd quarter. Retirement Systems of Alabama now owns 330,106 shares of the medical research company’s stock valued at $32,951,000 after purchasing an additional 260,467 shares during the period. Chilton Investment Co. LLC raised its position in shares of Iqvia by 122.6% during the 2nd quarter. Chilton Investment Co. LLC now owns 431,645 shares of the medical research company’s stock valued at $43,087,000 after purchasing an additional 237,732 shares during the period. Finally, Unigestion Holding SA bought a new stake in shares of Iqvia during the 2nd quarter valued at $23,250,000. Institutional investors and hedge funds own 91.36% of the company’s stock.

In other Iqvia news, Director John G. Danhakl sold 370,470 shares of Iqvia stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $124.83, for a total value of $46,245,770.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John G. Danhakl sold 221,900 shares of Iqvia stock in a transaction on Friday, September 7th. The stock was sold at an average price of $126.63, for a total transaction of $28,099,197.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 601,586 shares of company stock worth $75,510,422. 6.00% of the stock is currently owned by insiders.

Several brokerages have recently commented on IQV. Robert W. Baird raised their price objective on shares of Iqvia from $143.00 to $146.00 and gave the company an “outperform” rating in a research report on Tuesday, October 2nd. UBS Group began coverage on shares of Iqvia in a research report on Tuesday, October 9th. They set a “buy” rating on the stock. Raymond James raised their price objective on shares of Iqvia from $136.00 to $145.00 and gave the company a “strong-buy” rating in a research report on Friday, August 31st. Argus set a $136.00 price objective on shares of Iqvia and gave the company a “buy” rating in a research report on Thursday, August 23rd. Finally, Piper Jaffray Companies restated a “hold” rating and set a $97.00 price objective on shares of Iqvia in a research report on Wednesday, July 25th. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $131.67.

Shares of NYSE IQV opened at $122.37 on Wednesday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.09 and a current ratio of 1.09. The firm has a market capitalization of $24.62 billion, a price-to-earnings ratio of 28.07, a P/E/G ratio of 1.75 and a beta of 0.81. Iqvia Holdings Inc has a 52-week low of $91.57 and a 52-week high of $135.48.

Iqvia (NYSE:IQV) last announced its quarterly earnings results on Monday, October 22nd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.03. The company had revenue of $2.59 billion for the quarter, compared to the consensus estimate of $2.58 billion. Iqvia had a net margin of 12.29% and a return on equity of 13.69%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. On average, equities analysts forecast that Iqvia Holdings Inc will post 5.13 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece was reported by Week Herald and is owned by of Week Herald. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://weekherald.com/2018/11/07/renaissance-technologies-llc-sells-326147-shares-of-iqvia-holdings-inc-iqv.html.

Iqvia Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Featured Article: Diversification Important in Investing

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply